According to a new market report published by Transparency Market Research “Anxiety Disorders and Depression Treatment Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020”, the global anxiety disorders and depression treatment market was valued at USD 22.5 billion in 2013 and is expected to reach USD 18.2 billion in 2020, at a CAGR of (1.25%) from 2014 to 2020.

Anxiety is a biological reaction to stress, trauma and fear, which can be experienced by anyone in their lifetime, whereas depression is a mental state of low mood and aversion to daily activities that can affect an individual’s feelings, thoughts, sense of well-being and behavior. Depression affects 10% to 15% men and about 10% to 25% women. According to the World Health Organization (WHO), to date, over 350 million people have been affected by depression globally. The Anxiety and Depression Association of America revealed that at present approximately 40 million people in the U.S. are suffering from anxiety disorder and treating these patients costs around USD 42 billion each year. Thus, high prevalence of anxiety disorders and depression helped the market to transform itself into a billion dollar industry. However, the current scenario indicates that the overall anxiety disorders and depression treatment market would decline due to patent expiry of major antidepressants, weak pipeline of novel drugs and increasing number of generic drug variants.

Browse the full Anxiety Disorders and Depression Treatment Market Report at http://www.transparencymarketresearch.com/anxiety-disorders-depression-treatments.html



The anxiety disorders and depression treatment market has been segmented based on the drug classes commonly used for the treatment of various types of anxiety disorders and depression such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tetracyclic antidepressants (TeCA), monoamine oxidase inhibitors (MAOIs), benzodiazepines, atypical antipsychotics, anticonvulsants and beta blockers. SNRIs accounted for the largest share of over 30% of the depression treatment market in 2013. However, the segment is expected to witness a decline in revenue in the near future, reporting a CAGR of 14.2% from 2012 to 2016 and a CAGR of 4.3% from 2016 to 2020. Increasing influx of generic formulations as well as patent expiry of leading branded formulations such as Cymbalta, Lexapro and Effexor XR are some of the major factors that would negatively affect the growth of the segment. Moreover, with the loss of patent exclusivity, generics would offer physicians a broad range of affordable medications to prescribe, thereby significantly reducing the overall size of the anxiety disorders and depression treatment market. Hence, the future growth of the market would depend on commercialization of novel drugs for new indications.

Major pipeline drugs identified and expected to be launched during the forecast period from 2014 to 2020 include Brintellix [(Vortioxetine-Lu AA21004) (Lundbeck and Takeda)], Brexpiprazole [(OPC-34712) (Otsuka)] and ALKS-5461 [(FDC-buprenorphine and samidorphan) (Alkermes plc)]. The positive clinical trial outcomes of these drugs and anticipated commercialization during the forecast period are expected to fuel the growth of antidepressants and anxiolytic drugs market in the near future.

Geographically, North America accounted for the largest share of the anxiety disorders and depression treatment market in 2013 (over 35%). The U.S. accounted for the highest share of the revenue for each drug class due to the presence of one or more branded formulations that influenced the market dynamics significantly. However, the anxiety disorders and depression treatment market in the U.S. is currently saturated due to the presence of cheap generic products and several antidepressant drugs available on prescription for the same indication. Hence, the region is expected to witness a negative CAGR throughout the forecast period from 2014 to 2020. Asia Pacific is estimated to witness an appreciable growth rate (0.02%) due to various factors such as positive marketing approval for novel medicines, growing geriatric population and presence of a large population base in the region. Additionally, strong economic growth in countries such as China, Japan, New Zealand and Australia would contribute to the growth of the market in Asia Pacific.

Browse the full Press Release :http://www.transparencymarketresearch.com/pressrelease/anxiety-disorders-depression-treatments.htm

The market displays intense competitive rivalry among existing players, as currently the market for antidepressant and anxiolytic drugs is highly fragmented comprising both large and small manufacturers. Major market players include AstraZeneca plc, Eli Lilly and Company, Forest Laboratories, Inc., H. Lundbeck A/S, GlaxoSmithKline plc, Johnson & Johnson and Merck & Co., Inc. Eli Lilly and Company held the largest share of over 30% of the total anxiety disorders and depression treatment market in 2013. Product efficacy, differentiation, safety, well-developed distribution networks, and supply capabilities played a major role in determining the market position of the company.


The global anxiety disorders and depression treatment market has been segmented as follows:
Anxiety Disorders and Depression Treatment Market, by Drug Class
Selective Serotonin Reuptake Inhibitors (SSRIs)
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Atypical Antipsychotics
Tricyclic Antidepressants (TCAs)
Tetracyclic Antidepressants (TeCAs)
Monoamine Oxidase inhibitors (MAOIs)
Benzodiazepines
Beta-Blockers
Anticonvulsants
Anxiety Disorders and Depression Treatment Market, by Geography
North America
Europe
Asia-Pacific
Rest of the World (RoW)

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1199


About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.